
## Elena RamÃ-rez GarcÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4336324/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	6.3	316
2	A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. Journal of Clinical Medicine, 2020, 9, 1733.	1.0	218
3	Cyclosporine Use in Epidermal Necrolysis IsÂAssociated with an Important MortalityÂReduction: Evidence from ThreeÂDifferentÂApproaches. Journal of Investigative Dermatology, 2017, 137, 2092-2100.	0.3	112
4	Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System. British Journal of Clinical Pharmacology, 2010, 70, 694-702.	1.1	70
5	Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection. Therapeutic Drug Monitoring, 2009, 31, 436-442.	1.0	67
6	A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients. Clinical Pharmacology and Therapeutics, 2010, 87, 74-86.	2.3	67
7	Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital. Current Clinical Pharmacology, 2010, 5, 288-297.	0.2	67
8	Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacological Research, 2017, 115, 168-178.	3.1	61
9	Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 229-253.	0.6	57
10	An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease. PLoS ONE, 2012, 7, e41360.	1.1	52
11	Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: Results from a retrospective cohort study. Thrombosis Research, 2014, 133, 1045-1051.	0.8	52
12	Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clinical and Experimental Allergy, 2018, 48, 325-333.	1.4	49
13	Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. European Journal of Pharmacology, 2010, 626, 200-204.	1.7	43
14	Effectiveness and limitations of an incident-reporting system analyzed by local clinical safety leaders in a tertiary hospital. Medicine (United States), 2018, 97, e12509.	0.4	39
15	Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. Clinical and Translational Science, 2018, 11, 189-199.	1.5	37
16	Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested caseâ€control in a retrospective cohort study. Clinical and Experimental Allergy, 2013, 43, 344-352.	1.4	35
17	DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpevirus 6 in an 11-year-old caucasian boy. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 365-370.	0.7	27
18	Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. British Journal of Clinical Pharmacology, 2017, 83, 400-415.	1.1	27

#	Article	IF	CITATIONS
19	Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid. European Journal of Clinical Pharmacology, 2008, 64, 1031-1032.	0.8	26
20	Severe Hyponatremia Is Often Drug Induced: 10‥ear Results of a Prospective Pharmacovigilance Program. Clinical Pharmacology and Therapeutics, 2019, 106, 1362-1379.	2.3	21
21	Sublingual administration of tacrolimus in a renal transplant patient. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 87-89.	0.7	20
22	Assessment of drug causality in Stevensâ€Johnson syndrome/toxic epidermal necrolysis: Concordance between lymphocyte transformation test and ALDEN. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 956-959.	2.7	20
23	Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals. Journal of Clinical Medicine, 2021, 10, 4432.	1.0	20
24	Improving linezolid use decreases the incidence of resistance among Gram-positive microorganisms. International Journal of Antimicrobial Agents, 2013, 41, 174-178.	1.1	18
25	Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals. European Journal of Clinical Pharmacology, 2013, 69, 97-110.	0.8	18
26	Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. British Journal of Dermatology, 2016, 175, 604-607.	1.4	18
27	Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data. Frontiers in Pharmacology, 2020, 11, 602841.	1.6	18
28	Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand?. Regulatory Toxicology and Pharmacology, 2015, 72, 370-378.	1.3	17
29	Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. International Journal of Antimicrobial Agents, 2019, 54, 463-470.	1.1	17
30	Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. European Journal of Clinical Pharmacology, 2019, 75, 237-246.	0.8	16
31	Outcomes and Costs of Poisoned Patients Admitted to an Adult Emergency Department of a Spanish Tertiary Hospital: Evaluation through a Toxicovigilance Program. PLoS ONE, 2016, 11, e0152876.	1.1	14
32	Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. Pediatric Nephrology, 2014, 29, 117-123.	0.9	13
33	Active surveillance of severe cutaneous adverse reactions: A caseâ€population approach using a registry and a health care database. Pharmacoepidemiology and Drug Safety, 2018, 27, 1042-1050.	0.9	12
34	Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. Frontiers in Pharmacology, 2020, 11, 600255.	1.6	11
35	Valproic Acid-Induced Liver Injury: A Case-Control Study from a Prospective Pharmacovigilance Program in a Tertiary Hospital. Journal of Clinical Medicine, 2021, 10, 1153.	1.0	11
36	Vancomycin-Induced Acute Kidney Injury Detected by a Prospective Pharmacovigilance Program From Laboratory Signals. Therapeutic Drug Monitoring, 2013, 35, 360-366.	1.0	10

#	Article	IF	CITATIONS
37	The importance of sample size, log-mean ratios, and intrasubject variability in the acceptance criteria of 108 bioequivalence studies. European Journal of Clinical Pharmacology, 2008, 64, 783-793.	0.8	9
38	CYP2C9 polymorphism in five autochthonous population of the same geographic area (Spanish) Tj ETQq0 0 0 rg	gBT /Overlo	ock <sub>9</sub> 10 Tf 50 7

39	HLA-Aâ^—68, -Aâ^—11:01, and -Aâ^—29:02 alleles are strongly associated with benznidazole-induced maculopap exanthema (MPE)/DRESS. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3198-3200.e3.	ular 2.0	9
40	Nonâ€Chemotherapyâ€Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 399-408.	1.2	8
41	Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. Pediatric Hematology and Oncology, 2016, 33, 441-456.	0.3	8
42	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. Pharmaceuticals, 2022, 15, 78.	1.7	8
43	Use of antifungal agents in pediatric and adult high-risk areas. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 337-347.	1.3	7
44	The <i>HLA-B*15:02</i> allele in a Spanish Romani patient with carbamazepine-induced Stevens–Johnson syndrome. Pharmacogenomics, 2016, 17, 541-545.	0.6	7
45	Hepatotoxicity induced by acute and chronic paracetamol overdose in children: Where do we stand?. World Journal of Pediatrics, 2017, 13, 76-83.	0.8	7
46	Lymphocyte Transformation Test (LTT) in Allergy to Benznidazole: A Promising Approach. Frontiers in Pharmacology, 2019, 10, 469.	1.6	7
47	Liver Transplant in a Patient under Methylphenidate Therapy: A Case Report and Review of the Literature. Case Reports in Pediatrics, 2015, 2015, 1-5.	0.2	6
48	A case report of a drugâ€induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing. Clinical Case Reports (discontinued), 2020, 8, 3105-3109.	0.2	5
49	Lymphocyte transformation test can be useful for the diagnosis of delayed adverse reactions to sulfonamides. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3267-3272.	2.7	5
50	Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study. Frontiers in Pharmacology, 2022, 13, 819589.	1.6	5
51	Hypersensitivity reactions to contrast media injections: a nested case–control study. Annals of Allergy, Asthma and Immunology, 2014, 113, 488-489.e5.	0.5	4
52	Oseltamivir-induced toxic epidermal necrolysis in a patient with Cushing's disease. Indian Journal of Dermatology, Venereology and Leprology, 2020, 86, 515.	0.2	4
53	Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation. Frontiers in Pharmacology, 2021, 12, 717932.	1.6	4
54	A Preliminary Model to Avoid the Overestimation of Sample Size in Bioequivalence Studies. Drug Research, 2013, 63, 98-103.	0.7	2

#	Article	IF	CITATIONS
55	Approach to Severe Cutaneous Adverse Drug Reactions. Current Treatment Options in Allergy, 2017, 4, 201-221.	0.9	2
56	Health Care Workers' Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study. Journal of Medical Internet Research, 2021, 23, e23441.	2.1	2
57	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. BMJ Open, 2020, 10, e037443.	0.8	2
58	Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population. Pharmacogenomics, 2017, 18, 797-805.	0.6	1
59	A case ontrol study to assess the role of polyomavirus in transplant complications: Where do we stand?. Transplant Infectious Disease, 2020, 22, e13432.	0.7	1
60	Identifying the Culprit Drug in Severe Cutaneous Adverse Reactions (SCARs). Current Treatment Options in Allergy, 2021, 8, 194-209.	0.9	1
61	Early Detection of Chemotherapy- Induced Cardiotoxicity in Hematological Patients: A Prospective Study. Blood, 2016, 128, 5988-5988.	0.6	1
62	Severe hypersensitivity reactions to iodinated contrast media: clinical and immunological features in a cohort of patients. Clinical and Translational Allergy, 2014, 4, P131.	1.4	0
63	Uam Course on Good Clinical Practice (Gcps) for Investigators: A 3 Years Experience. Clinical Therapeutics, 2015, 37, e129.	1.1	0
64	A Pharmacovigilance Program from Laboratory Signals In Hospitalizaed Patients: Results Of 2014. Clinical Therapeutics, 2015, 37, e137.	1.1	0
65	Pharmacogenetic Implementation In The Routine Clinical Practice: Design of A Multicenter Pilot Clinical Trial. Clinical Therapeutics, 2015, 37, e129-e130.	1.1	0
66	Cytochrome P450 Oxidoreductase Contribution On An Acenocoumarol Dosing Algorithm. Clinical Therapeutics, 2015, 37, e131.	1.1	0
67	Screening and Recruitment Procedures of Healthy Volunteers In A Phase I Clinical Trial Unit: Experience In 64 Bioequivalence Studies. Clinical Therapeutics, 2015, 37, e129.	1.1	0
68	A Computerized System for Reporting and Analysis of Incidents, Errors or Adverse Events: Results Of 2014. Clinical Therapeutics, 2015, 37, e136-e137.	1.1	0